TCGA-C8-A26V-01A-11R-A16F-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 21
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.580
- PROTEIN_SECRETION+0.490
- OXIDATIVE_PHOSPHORYLATION+0.460
- INTERFERON_GAMMA_RESPONSE+0.430
- GLYCOLYSIS+0.380
- MTORC1_SIGNALING+0.360
- PEROXISOME+0.310
- ADIPOGENESIS+0.270
- HEME_METABOLISM+0.270
- FATTY_ACID_METABOLISM+0.260
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.420
- ANGIOGENESIS-0.270
- PANCREAS_BETA_CELLS-0.250
- NOTCH_SIGNALING-0.240
- KRAS_SIGNALING_DN-0.220
- MYOGENESIS-0.220
- APICAL_SURFACE-0.210
- KRAS_SIGNALING_UP-0.210
- IL6_JAK_STAT3_SIGNALING-0.190
- MYC_TARGETS_V2-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013565 | — | cohortA4 | 0.812 |
| 2 | BS_CZ3ER8DY | Supratentorial Ependymoma | — | 0.807 |
| 3 | BS_W80TJC27 | Supratentorial Ependymoma | — | 0.797 |
| 4 | TCGA-A2-A0YT-01A-11R-A109-07 | — | B | 0.781 |
| 5 | TCGA-AR-A24N-01A-11R-A169-07 | — | B | 0.780 |
| 6 | TCGA-DK-AA77-01A-11R-A39I-07 | — | — | 0.768 |
| 7 | SRR8942934 | — | — | 0.767 |
| 8 | TCGA-D8-A1JT-01A-31R-A13Q-07 | — | B | 0.767 |
| 9 | TCGA-95-7562-01A-11R-2241-07 | — | cohortA4 | 0.756 |
| 10 | BS_CZ3NA7KV | Supratentorial Ependymoma | — | 0.755 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.580 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.490 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.380 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| PEROXISOME | 0.310 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.270 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |